Cassipharma SPRL
2.1 FTECassipharma reported total assets of 548,988 € at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Jan 2026), with 2.1 full-time equivalents.
The score of Cassipharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -70 % Total assets -68 % Headcount (avg FTE) -19 %
Accounts of the company itself (not consolidated).
The full file covers 14 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Cassipharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 8,177 € | ||||
| Equity | 217,796 € | ||||
| Cash | 294,389 € | ||||
| EBITDA | 5,930 € | ||||
| Total assets | 548,988 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 30 Jan 2026
- Year ended 30 Jun 2024filed on 31 Jan 2025
- Year ended 30 Jun 2023filed on 31 Jan 2024
- Year ended 30 Jun 2022filed on 19 Jan 2023
- Year ended 30 Jun 2021filed on 31 Jan 2022
Cassipharma's financial analysis
- Solvency39.7%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Cassipharma
Cassipharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0477.736.777
- VAT number
- BE0477736777
- Peppol
- Registered · 0208:0477736777 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 12 Jun 2002
- Registered office
- 9000 Ghent
- Size
- Micro · 2.1 FTE
- Latest accounts
- 2025 · filed on 30 Jan 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Cassipharma (SPRL) has been based in Ghent since 2002, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 8,177 € and equity of 217,796 €; its revenue is not published. With 2.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 39.7%, below the median of its sector (44.2%).
Companies similar to Cassipharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek AN Leyman Retail sale of pharmaceutical products Ghent · balance sheet 551,428 €
- Verbofar Retail sale of pharmaceutical products Deinze · balance sheet 548,560 €
- Pharmacie DU Cinquantenaire Retail sale of pharmaceutical products Uccle · balance sheet 548,448 €
- De Nil Retail sale of pharmaceutical products Dendermonde · balance sheet 551,344 €
- Gilis-Segers Retail sale of pharmaceutical products Tienen · balance sheet 545,887 €
- Naveau-Smeets Retail sale of pharmaceutical products Lint · balance sheet 552,659 €
- VAN EYCKEN Apotheek-Optiek Retail sale of pharmaceutical products Diest · balance sheet 553,302 €
- APLV Retail sale of pharmaceutical products Bornem · balance sheet 542,377 €
Frequently asked questions about Cassipharma
What is the revenue of Cassipharma?
Cassipharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Cassipharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0477736777 for Cassipharma, if the company is VAT-registered. Its company number (CBE) is 0477.736.777.
Where is the registered office of Cassipharma?
According to the CBE register, the registered office of Cassipharma is in 9000 Ghent.
What is the equity of Cassipharma?
At the close of the 2025 financial year, the equity of Cassipharma amounts to 217,796 €, a solvency of 39.7% of total assets.
How many people work at Cassipharma?
2.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Cassipharma?
The register lists 2 active mandates at Cassipharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Cassipharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →